2. Fotbolcu H, Zorlu E. Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol 2016;22:4079-90.
[CROSSREF] [PUBMED] [PMC]
3. Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol 2021;17:484-95.
[CROSSREF] [PUBMED] [PMC]
4. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62(1 Suppl):S47-64.
[CROSSREF] [PUBMED]
5. Chao HW, Chao SW, Lin H, Ku HC, Cheng CF. Homeostasis of glucose and lipid in non-alcoholic fatty liver disease. Int J Mol Sci 2019;20:298.
[CROSSREF] [PMC]
6. Pei K, Gui T, Kan D, Feng H, Jin Y, Yang Y, et al. An overview of lipid metabolism and nonalcoholic fatty liver disease. Biomed Res Int 2020;2020:4020249.
[CROSSREF] [PUBMED] [PMC]
7. Oh CM, Park S, Kim H. Serotonin as a new therapeutic target for diabetes mellitus and obesity. Diabetes Metab J 2016;40:89-98.
[CROSSREF] [PUBMED] [PMC]
8. Yabut JM, Crane JD, Green AE, Keating DJ, Khan WI, Steinberg GR. Emerging roles for serotonin in regulating metabolism: new implications for an ancient molecule. Endocr Rev 2019;40:1092-107.
[CROSSREF] [PUBMED] [PMC]
9. Badawy AA. Kynurenine pathway of tryptophan metabolism: regulatory and functional aspects. Int J Tryptophan Res 2017;10:1178646917691938.
[CROSSREF] [PUBMED] [PMC]
10. Nakamura K, Hasegawa H. Developmental role of tryptophan hydroxylase in the nervous system. Mol Neurobiol 2007;35:45-54.
[CROSSREF] [PUBMED]
11. Prah A, Purg M, Stare J, Vianello R, Mavri J. How monoamine oxidase a decomposes serotonin: an empirical valence bond simulation of the reactive step. J Phys Chem B 2020;124:8259-65.
[CROSSREF] [PUBMED] [PMC]
12. Gauer F, Craft CM. Circadian regulation of hydroxyindole-O-methyltransferase mRNA levels in rat pineal and retina. Brain Res 1996;737:99-109.
[CROSSREF] [PUBMED]
13. Pissios P, Maratos-Flier E. More than satiety: central serotonin signaling and glucose homeostasis. Cell Metab 2007;6:345-7.
[CROSSREF] [PUBMED] [PMC]
14. van Galen KA, Ter Horst KW, Serlie MJ. Serotonin, food intake, and obesity. Obes Rev 2021;22:e13210.
[PUBMED] [PMC]
15. Namkung J, Kim H, Park S. Peripheral serotonin: a new player in systemic energy homeostasis. Mol Cells 2015;38:1023-8.
[CROSSREF] [PUBMED] [PMC]
16. Vandenbussche N, Goadsby PJ. Lorcaserin safety in overweight or obese patients. N Engl J Med 2019;380:99.
[CROSSREF]
17. Sharretts J, Galescu O, Gomatam S, Andraca-Carrera E, Hampp C, Yanoff L. Cancer risk associated with lorcaserin: the FDA’s review of the CAMELLIA-TIMI 61 Trial. N Engl J Med 2020;383:1000-2.
[CROSSREF] [PUBMED]
18. Cano G, Passerin AM, Schiltz JC, Card JP, Morrison SF, Sved AF. Anatomical substrates for the central control of sympathetic outflow to interscapular adipose tissue during cold exposure. J Comp Neurol 2003;460:303-26.
[CROSSREF] [PUBMED]
19. Madden CJ, Morrison SF. Endogenous activation of spinal 5-hydroxytryptamine (5-HT) receptors contributes to the thermoregulatory activation of brown adipose tissue. Am J Physiol Regul Integr Comp Physiol 2010;298:R776-83.
[CROSSREF] [PUBMED] [PMC]
20. McGlashon JM, Gorecki MC, Kozlowski AE, Thirnbeck CK, Markan KR, Leslie KL, et al. Central serotonergic neurons activate and recruit thermogenic brown and beige fat and regulate glucose and lipid homeostasis. Cell Metab 2015;21:692-705.
[CROSSREF] [PUBMED] [PMC]
21. Berglund ED, Liu C, Sohn JW, Liu T, Kim MH, Lee CE, et al. Serotonin 2C receptors in pro-opiomelanocortin neurons regulate energy and glucose homeostasis. J Clin Invest 2013;123:5061-70.
[CROSSREF] [PUBMED] [PMC]
22. Könner AC, Janoschek R, Plum L, Jordan SD, Rother E, Ma X, et al. Insulin action in AgRP-expressing neurons is required for suppression of hepatic glucose production. Cell Metab 2007;5:438-49.
[CROSSREF] [PUBMED]
23. Chandran S, Guo T, Tolliver T, Chen W, Murphy DL, McPherron AC. Effects of serotonin on skeletal muscle growth. BMC Proc 2012;6(Suppl 3):O3.
[CROSSREF]
24. Oh CM, Namkung J, Go Y, Shong KE, Kim K, Kim H, et al. Regulation of systemic energy homeostasis by serotonin in adipose tissues. Nat Commun 2015;6:6794.
[CROSSREF] [PUBMED]
25. Park H, Oh CM, Park J, Park H, Cui S, Kim HS, et al. Deletion of the serotonin receptor type 3A in mice leads to sudden cardiac death during pregnancy. Circ J 2015;79:1807-15.
[CROSSREF] [PUBMED]
26. Kim H, Toyofuku Y, Lynn FC, Chak E, Uchida T, Mizukami H, et al. Serotonin regulates pancreatic beta cell mass during pregnancy. Nat Med 2010;16:804-8.
[CROSSREF] [PUBMED] [PMC]
27. Li Z, Chalazonitis A, Huang YY, Mann JJ, Margolis KG, Yang QM, et al. Essential roles of enteric neuronal serotonin in gastrointestinal motility and the development/survival of enteric dopaminergic neurons. J Neurosci 2011;31:8998-9009.
[CROSSREF] [PUBMED] [PMC]
28. Shajib MS, Khan WI. The role of serotonin and its receptors in activation of immune responses and inflammation. Acta Physiol (Oxf) 2015;213:561-74.
[CROSSREF] [PUBMED]
29. Hoffman JM, Tyler K, MacEachern SJ, Balemba OB, Johnson AC, Brooks EM, et al. Activation of colonic mucosal 5-HT(4) receptors accelerates propulsive motility and inhibits visceral hypersensitivity. Gastroenterology 2012;142:844-54.
[CROSSREF] [PUBMED]
30. Liu MT, Kuan YH, Wang J, Hen R, Gershon MD. 5-HT4 receptor-mediated neuroprotection and neurogenesis in the enteric nervous system of adult mice. J Neurosci 2009;29:9683-99.
[CROSSREF] [PUBMED] [PMC]
31. Kwon YH, Wang H, Denou E, Ghia JE, Rossi L, Fontes ME, et al. Modulation of gut microbiota composition by serotonin signaling influences intestinal immune response and susceptibility to colitis. Cell Mol Gastroenterol Hepatol 2019;7:709-28.
[CROSSREF] [PUBMED] [PMC]
32. Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 2015;161:264-76.
[CROSSREF] [PUBMED] [PMC]
33. Ohara-Imaizumi M, Kim H, Yoshida M, Fujiwara T, Aoyagi K, Toyofuku Y, et al. Serotonin regulates glucose-stimulated insulin secretion from pancreatic β cells during pregnancy. Proc Natl Acad Sci U S A 2013;110:19420-5.
[CROSSREF] [PUBMED] [PMC]
34. Kim K, Oh CM, Ohara-Imaizumi M, Park S, Namkung J, Yadav VK, et al. Functional role of serotonin in insulin secretion in a diet-induced insulin-resistant state. Endocrinology 2015;156:444-52.
[CROSSREF] [PUBMED]
35. Moon JH, Kim YG, Kim K, Osonoi S, Wang S, Saunders DC, et al. Serotonin regulates adult β-cell mass by stimulating perinatal β-cell proliferation. Diabetes 2020;69:205-14.
[CROSSREF] [PUBMED]
36. Sumara G, Sumara O, Kim JK, Karsenty G. Gut-derived serotonin is a multifunctional determinant to fasting adaptation. Cell Metab 2012;16:588-600.
[CROSSREF] [PUBMED] [PMC]
37. Savelieva KV, Zhao S, Pogorelov VM, Rajan I, Yang Q, Cullinan E, et al. Genetic disruption of both tryptophan hydroxylase genes dramatically reduces serotonin and affects behavior in models sensitive to antidepressants. PLoS One 2008;3:e3301.
[CROSSREF] [PUBMED] [PMC]
38. Gutknecht L, Araragi N, Merker S, Waider J, Sommerlandt FM, Mlinar B, et al. Impacts of brain serotonin deficiency following Tph2 inactivation on development and raphe neuron serotonergic specification. PLoS One 2012;7:e43157.
[CROSSREF] [PUBMED] [PMC]
39. Shong KE, Oh CM, Namkung J, Park S, Kim H. Serotonin regulates de novo lipogenesis in adipose tissues through serotonin receptor 2A. Endocrinol Metab (Seoul) 2020;35:470-9.
[CROSSREF] [PUBMED] [PMC]
40. Crane JD, Palanivel R, Mottillo EP, Bujak AL, Wang H, Ford RJ, et al. Inhibiting peripheral serotonin synthesis reduces obesity and metabolic dysfunction by promoting brown adipose tissue thermogenesis. Nat Med 2015;21:166-72.
[CROSSREF] [PUBMED]
41. Omenetti A, Yang L, Gainetdinov RR, Guy CD, Choi SS, Chen W, et al. Paracrine modulation of cholangiocyte serotonin synthesis orchestrates biliary remodeling in adults. Am J Physiol Gastrointest Liver Physiol 2011;300:G303-15.
[CROSSREF] [PUBMED]
42. Ruddell RG, Mann DA, Ramm GA. The function of serotonin within the liver. J Hepatol 2008;48:666-75.
[CROSSREF] [PUBMED]
43. Richardson PD, Withrington PG. A comparison of the effects of bradykinin, 5-hydroxytryptamine and histamine on the hepatic arterial and portal venous vascular beds of the dog: histamine H1 and H2-receptor populations. Br J Pharmacol 1977;60:123-33.
[CROSSREF] [PUBMED] [PMC]
44. Cummings SA, Groszmann RJ, Kaumann AJ. Hypersensitivity of mesenteric veins to 5-hydroxytryptamine- and ketanserin-induced reduction of portal pressure in portal hypertensive rats. Br J Pharmacol 1986;89:501-13.
[CROSSREF] [PUBMED] [PMC]
45. Cummings JL, Cilento EV, Reilly FD. Hepatic microvascular regulatory mechanisms. XII. Effects of 5-HT2-receptor blockade on serotonin-induced intralobular hypoperfusion. Int J Microcirc Clin Exp 1993;13:99-112.
[PUBMED]
46. Kulinskii AS, Saratikov AS, Vstavskaia IuA, Udovitsina TI. Effect of substances altering the metabolism of endogenous serotonin on mitotic activity in the regenerating liver of mice. Farmakol Toksikol 1983;46:92-5.
47. Kulinskii VI, Saratikov AS, Vstavskaia IuA, Udovitsina TI. Receptors mediating serotonin-stimulating liver regeneration in mice. Biull Eksp Biol Med 1983;95:89-91.
48. Papadimas GK, Tzirogiannis KN, Mykoniatis MG, Grypioti AD, Manta GA, Panoutsopoulos GI. The emerging role of serotonin in liver regeneration. Swiss Med Wkly 2012;142:w13548.
[CROSSREF] [PUBMED]
49. Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, et al. Platelet-derived serotonin mediates liver regeneration. Science 2006;312:104-7.
[CROSSREF] [PUBMED]
50. Ebrahimkhani MR, Oakley F, Murphy LB, Mann J, Moles A, Perugorria MJ, et al. Stimulating healthy tissue regeneration by targeting the 5-HT2B receptor in chronic liver disease. Nat Med 2011;17:1668-73.
[CROSSREF] [PUBMED] [PMC]
51. Fang Y, Liu C, Shu B, Zhai M, Deng C, He C, et al. Axis of serotonin: pERK-YAP in liver regeneration. Life Sci 2018;209:490-7.
[CROSSREF] [PUBMED]
52. Starlinger P, Pereyra D, Hackl H, Ortmayr G, Braunwarth E, Santol J, et al. Consequences of perioperative serotonin reuptake inhibitor treatment during hepatic surgery. Hepatology 2021;73:1956-66.
[CROSSREF] [PUBMED]
53. Moore MC, DiCostanzo CA, Dardevet D, Lautz M, Farmer B, Neal DW, et al. Portal infusion of a selective serotonin reuptake inhibitor enhances hepatic glucose disposal in conscious dogs. Am J Physiol Endocrinol Metab 2004;287:E1057-63.
[CROSSREF] [PUBMED]
54. Haub S, Ritze Y, Ladel I, Saum K, Hubert A, Spruss A, et al. Serotonin receptor type 3 antagonists improve obesity-associated fatty liver disease in mice. J Pharmacol Exp Ther 2011;339:790-8.
[CROSSREF] [PUBMED]
55. Choi W, Namkung J, Hwang I, Kim H, Lim A, Park HJ, et al. Serotonin signals through a gut-liver axis to regulate hepatic steatosis. Nat Commun 2018;9:4824.
[CROSSREF] [PUBMED] [PMC]
56. Ruddell RG, Oakley F, Hussain Z, Yeung I, Bryan-Lluka LJ, Ramm GA, et al. A role for serotonin (5-HT) in hepatic stellate cell function and liver fibrosis. Am J Pathol 2006;169:861-76.
[CROSSREF] [PUBMED] [PMC]
57. Kim DC, Jun DW, Kwon YI, Lee KN, Lee HL, Lee OY, et al. 5-HT2A receptor antagonists inhibit hepatic stellate cell activation and facilitate apoptosis. Liver Int 2013;33:535-43.
[CROSSREF] [PUBMED]
58. Choi WG, Choi W, Oh TJ, Cha HN, Hwang I, Lee YK, et al. Inhibiting serotonin signaling through HTR2B in visceral adipose tissue improves obesity related insulin resistance. J Clin Invest 2021 Oct 7 [Epub].
https://doi.org/10.1172/JCI145331
.
[CROSSREF]
59. Wegermann K, Howe C, Henao R, Wang Y, Guy CD, Abdelmalek MF, et al. Serum bile acid, vitamin E, and serotonin metabolites are associated with future liver-related events in nonalcoholic fatty liver disease. Hepatol Commun 2021;5:608-17.
[CROSSREF] [PUBMED] [PMC]
60. Binetti J, Bertran L, Riesco D, Aguilar C, Martinez S, Sabench F, et al. Deregulated serotonin pathway in women with morbid obesity and NAFLD. Life (Basel) 2020;10:245.
[CROSSREF] [PMC]
61. Pantano L, Agyapong G, Shen Y, Zhuo Z, Fernandez-Albert F, Rust W, et al. Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD. Sci Rep 2021;11:18045.
[CROSSREF] [PUBMED] [PMC]
62. Horst DA, Grace ND, LeCompte PM. Prolonged cholestasis and progressive hepatic fibrosis following imipramine therapy. Gastroenterology 1980;79:550-4.
[CROSSREF] [PUBMED]
63. Le Bricquir Y, Larrey D, Blanc P, Pageaux GP, Michel H. Tianeptine: an instance of drug-induced hepatotoxicity predicted by prospective experimental studies. J Hepatol 1994;21:771-3.
[PUBMED]
64. Levine B, Jenkins AJ, Queen M, Jufer R, Smialek JE. Distribution of venlafaxine in three postmortem cases. J Anal Toxicol 1996;20:502-5.
[CROSSREF] [PUBMED]
65. Vuppalanchi R, Hayashi PH, Chalasani N, Fontana RJ, Bonkovsky H, Saxena R, et al. Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network. Aliment Pharmacol Ther 2010;32:1174-83.
[CROSSREF] [PUBMED] [PMC]
66. Ayyash A, Holloway AC. Fluoxetine-induced hepatic lipid accumulation is linked to elevated serotonin production. Can J Physiol Pharmacol 2021;99:983-8.
[CROSSREF] [PUBMED]
67. Pan SJ, Tan YL, Yao SW, Xin Y, Yang X, Liu J, et al. Fluoxetine induces lipid metabolism abnormalities by acting on the liver in patients and mice with depression. Acta Pharmacol Sin 2018;39:1463-72.
[CROSSREF] [PUBMED] [PMC]
68. Tuccinardi D, Farr OM, Upadhyay J, Oussaada SM, Mathew H, Paschou SA, et al. Lorcaserin treatment decreases body weight and reduces cardiometabolic risk factors in obese adults: a six-month, randomized, placebo-controlled, double-blind clinical trial. Diabetes Obes Metab 2019;21:1487-92.
[CROSSREF] [PUBMED] [PMC]
69. Cerpa V, Gonzalez A, Richerson GB. Diphtheria toxin treatment of Pet-1-Cre floxed diphtheria toxin receptor mice disrupts thermoregulation without affecting respiratory chemoreception. Neuroscience 2014;279:65-76.
[CROSSREF] [PUBMED]
70. Wyler SC, Lord CC, Lee S, Elmquist JK, Liu C. Serotonergic control of metabolic homeostasis. Front Cell Neurosci 2017;11:277.
[CROSSREF] [PUBMED] [PMC]
71. Choi W, Moon JH, Kim H. Serotonergic regulation of energy metabolism in peripheral tissues. J Endocrinol 2020;245:R1-10.
[CROSSREF] [PUBMED]
72. Wang L, Fan X, Han J, Cai M, Wang X, Wang Y, et al. Gut-derived serotonin contributes to the progression of non-alcoholic steatohepatitis via the liver HTR2A/PPARγ2 pathway. Front Pharmacol 2020;11:553.
[CROSSREF] [PUBMED] [PMC]